Skip to main contentShah's Gastro, Cancer & Robotic Surgery Centre · Ahmedabad & Gandhinagar
Hepatocellular carcinoma treatment in Ahmedabad · Gota OPD, Ahmedabad · Apollo Hospital, Bhat, Gandhinagar
Hepatocellular carcinoma (HCC), the commonest cancer that starts in the liver itself, almost always grows in a liver that is already damaged — by hepatitis B or C, alcohol or fatty liver disease. So two diseases are treated at once: the tumour and the liver around it. The choice between removing the tumour, a liver transplant, burning it with a needle (ablation), blocking its blood supply with chemotherapy (TACE) and medicines given by mouth or drip depends on three things together — how many tumours and how large, how well the rest of the liver works, and how fit the patient is. A tumour that could technically be cut out is not operable if the liver left behind would fail.
HCC is the gastro cancer where a decision made by one specialist alone does most harm. The surgeon, the liver physician, the interventional radiologist who performs ablation and TACE, the oncologist and the transplant team look at every case together before treatment begins — and early, while every option is still open.
Shah’s Gastro, Cancer & Robotic Surgery Centre. Trained in super-specialty surgical gastroenterology programmes, qualified twice over in the specialty, with 18 years of experience in liver and gastro cancer surgery. Multiphasic CT and MRI review, liver-function assessment, liver resection by open and keyhole routes, coordination of ablation, TACE and systemic treatment, transplant referral and lifelong surveillance sit within one practice.
Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Liver Cancer Surgeon · Apollo Hospital, Bhat, Gandhinagar · Gota OPD, Ahmedabad
Google rating 4.89 from 216 reviews at the Gota clinic, and 4.94 from 18 reviews at Apollo, Bhat.
Most HCC is found in people who already have cirrhosis (scarring of the liver) of any cause, people with long-standing hepatitis B even without cirrhosis, and people with advanced scarring from fatty liver disease — an increasingly common story in India. The liver’s reserve, not just the tumour, sets the limits of every treatment, and the cause of the liver disease has to be treated alongside the cancer.
HCC is ideally found before it causes symptoms. People at risk — anyone with cirrhosis, certain people with hepatitis B, and people with advanced fatty-liver scarring — should have a liver ultrasound, with or without an AFP blood test, every six months. A small tumour found this way is far more likely to be suitable for treatment aimed at removing it completely.
Surveillance is offered to cirrhotics whose liver is still working reasonably, and to those with a badly failing liver only if they are being assessed for transplant. Among people with hepatitis B, older men and women of Asian origin, those with a family history of liver cancer and those with a high viral load are included even without cirrhosis. Newer European guidance moves toward setting the interval by each person’s risk rather than one interval for all.
In a liver already known to be at risk, HCC is usually diagnosed on a scan, not a biopsy. A nodule larger than one centimetre that shows the typical pattern on a contrast CT or MRI taken in several phases — lighting up brightly in the arterial phase and then “washing out” later — is HCC, and no biopsy is required.
Radiologists report these scans in a standard way (LI-RADS) so that a nodule is clearly placed as benign, probably benign, uncertain, probably HCC or definitely HCC. A biopsy is kept for when the scan pattern is not typical, when the liver is not cirrhotic, or when medicines are planned and the diagnosis is genuinely in doubt; it carries a small risk of seeding tumour cells along the needle track. A nodule smaller than one centimetre is re-scanned after three to four months rather than biopsied.
Not every spot in a liver is cancer. Regenerative nodules in cirrhosis, haemangiomas, cysts and other benign lesions are common, and the multiphase scan pattern and its standard report separate them from HCC. Other cancers can also appear in the liver — a bile duct cancer arising inside the liver, or spread from the bowel or another organ — and each is treated on its own pathway.
When the pattern is typical, the diagnosis is HCC. When it is uncertain, a repeat scan, an MRI with a liver-specific contrast, or a targeted biopsy settles it. A tumour that turns out to be a bile duct cancer, a mixed tumour, or spread from another cancer changes the treatment plan completely, which is why the diagnosis is confirmed before anything is decided.
Before any treatment, the tumour is mapped, the rest of the body is checked, and the liver’s strength is measured. That means a multiphase CT or MRI of the liver and a CT of the chest; blood tests of liver function, clotting and platelets; an assessment for raised pressure in the liver’s veins; AFP; the cause of the liver disease; and the patient’s day-to-day fitness.
| Test | What it decides |
|---|---|
| Multiphase CT and/or MRI of the liver | The diagnosis, the number and size of tumours, and any invasion of the main veins |
| CT of the chest | Whether the cancer has spread outside the liver |
| Child-Pugh score and ALBI grade (bilirubin, albumin, INR, fluid in the abdomen, confusion) | How much liver reserve there is — the gate every treatment must pass |
| Platelets, spleen size, endoscopy for varices | Whether there is clinically significant portal hypertension, the practical bar to a major resection; varices must be treated before some medicines |
| AFP | A baseline and a marker to follow over time — not a diagnosis on its own |
| Hepatitis B and C tests, alcohol history, metabolic profile | The cause of the liver disease, which is treated in every patient |
| Performance status (day-to-day fitness) | Whether the patient can safely take each treatment |
| Volumetry (measuring the liver that would remain) | Before any major resection — whether enough liver will be left to work |
The Child-Pugh class sorts the liver into well compensated (class A), moderately impaired (class B) and decompensated (class C). Resection is for class A livers with normal bilirubin and no significant portal hypertension. Class B patients gain much less, and take more side effects, from medicines. A class C liver is not treated with surgery, TACE or medicines for the cancer; the question becomes transplant assessment or supportive care.
A second measure, the ALBI grade, uses bilirubin and albumin to refine the picture, and both are written in every patient’s record. Raised pressure in the liver’s veins — shown by low platelets with varices, or measured directly — is the practical reason a technically removable tumour is not removed: the liver left behind would decompensate.
The Barcelona (BCLC) system links the size and number of tumours, the liver function and fitness to a first treatment. Very early and early HCC — a single small tumour, or up to three small ones — is treated with resection, ablation or transplant. Intermediate HCC — several tumours in the liver — is treated with TACE, with transplant after downstaging for some. Advanced HCC, with spread into the main veins or outside the liver, is treated with medicines. End-stage disease with a failing liver is treated with supportive care.
| Stage | Tumour | Liver and fitness | Usual first treatment |
|---|---|---|---|
| Very early | A single tumour up to two centimetres | Child-Pugh A, fully active | Resection or ablation |
| Early | A single tumour, or up to three each up to three centimetres | Child-Pugh A or B, fully active | Resection, ablation or transplant |
| Intermediate | Several tumours, beyond the transplant limits | Child-Pugh A or B, fully active | TACE; transplant after successful downstaging in selected patients; medicines if TACE is unsuitable or fails |
| Advanced | Invasion of the portal vein, or spread outside the liver | Child-Pugh A or B, mildly limited | Medicines (immunotherapy combinations first) |
| End-stage | Any | Child-Pugh C, or confined to bed much of the day | Supportive care; transplant assessment only if otherwise eligible |
The stage gives the starting point, not the final answer. A team may move a patient up or down the map — for example, offering resection to a fit patient with a single larger tumour and a strong liver, or moving to medicines early when TACE is unlikely to work. Those decisions are made together, case by case.
Resection suits a single tumour in a strong liver (Child-Pugh A, normal bilirubin, no significant portal hypertension). The part of the liver carrying the tumour is removed along the lines of its blood supply where possible, keeping a clear margin, while leaving enough healthy liver to work — more must be left in a cirrhotic liver than in a normal one.
Before any major resection, the liver that would remain is measured on the scan. If it is too small, the blood flow to the tumour side can be blocked beforehand (portal vein embolisation) so the other side grows. A narrow margin is accepted rather than leaving too little liver. Ultrasound is used inside the abdomen during every operation, because it often changes the plan. Keyhole (laparoscopic or robotic) liver resection is endorsed in current European guidance and is preferred for tumours on the surface or in the left outer segment, with less fluid in the abdomen and fewer wound problems — helpful in cirrhotic patients. No medicine after resection has proven benefit at present, so careful surveillance, not additional treatment, follows the operation.
A liver transplant removes both the cancer and the diseased liver that made it. It is considered for HCC within the Milan limits — one tumour up to five centimetres, or up to three tumours none larger than three centimetres, with no invasion of the major veins and no spread — or for tumours brought within those limits by treatment.
In India most transplants come from a living donor, usually a family member, because waiting times for a deceased-donor liver are long and unpredictable. The commonest reason a patient misses a transplant is late referral, not ineligibility, so the referral conversation for any possible candidate happens at the first visit, not after other treatments have run out. While waiting, ablation or TACE is used to hold the tumour back. Where transplant would be the guideline choice but is not possible — no suitable donor, for example — the reason is discussed honestly and recorded, and resection or ablation is chosen openly, not silently.
Radiofrequency or microwave ablation passes a needle into the tumour under scan guidance and destroys it with heat. It is a treatment aimed at complete removal for very early and early HCC up to about three centimetres, particularly when liver function rules out resection; for tumours up to two centimetres its results approach those of resection.
Ablation needs no incision in most patients and spares liver tissue, which matters in cirrhosis. Its limits are the size of the tumour and its position — next to a large vessel, the bowel or the diaphragm, a different approach may be safer. Where neither ablation nor TACE is suitable, focused radiotherapy (SBRT) is an option in selected patients.
TACE delivers chemotherapy directly into the tumour’s artery and then blocks the vessel, through a fine tube passed from the groin or wrist. It is the standard treatment for intermediate HCC. Its response is checked after each session, and it is stopped after two sessions that do not work, because repeating it uselessly damages the liver and can cost the patient the chance of medicines later.
Radioembolisation (TARE, Y-90) places tiny radioactive beads in the tumour’s artery instead. It is an option in selected patients, including some with tumour in the portal vein, and it can be used to shrink a tumour or to grow the opposite side of the liver before a resection. Fever, pain and nausea for a few days after TACE are expected; fever or pain lasting longer, or yellowing of the eyes, needs review.
For advanced HCC, or intermediate disease that has progressed on TACE or cannot have it, medicines are the first treatment. The preferred first choice is a combination of immunotherapy with a drug that blocks tumour blood vessels (atezolizumab with bevacizumab); another immunotherapy combination (durvalumab with tremelimumab) suits those with a high bleeding risk; tablets such as lenvatinib or sorafenib are used when immunotherapy is unsuitable.
Because bevacizumab and untreated varices are a dangerous combination, an endoscopy and treatment of varices come first. Further medicines are available if the first ones stop working. Patients with a moderately impaired liver are treated selectively, and medicines for the cancer are not given to a patient whose liver has failed.
Many patients with HCC are treated without any operation: a small tumour can be ablated through a needle, intermediate disease is treated through the artery, and advanced disease is treated with medicines. An operation is also not offered when the tumour could be removed but the liver could not survive it — decompensated cirrhosis, significant portal hypertension, or too small a remnant.
A rupture of HCC with bleeding into the abdomen is an emergency, but even then the first step is usually to block the bleeding artery through a catheter (angioembolisation) rather than an immediate open operation; a planned resection may follow once the patient is stable. And a patient with a failing liver and poor fitness is served by supportive care and, if eligible, transplant assessment — not by treatments that would shorten life.
In every patient, at every stage, the cause of the liver disease is treated: antiviral tablets to suppress hepatitis B, medicines that clear hepatitis C, support to stop alcohol, and control of weight, diabetes and fat in fatty liver disease. This is not an add-on — it changes long-term survival independent of the tumour.
★★★★★
“Met with Dr. Harsh Shah for the consultation of one of my relative. Dr. Harsh Shah is an exceptional surgical oncologist in Ahmedabad. His expertise in treating complex GI cancers like liver, pancreas, and colon cancers is truly remarkable. He explains everything clearly and gives patients full confidence in their treatment. Highly recommended for anyone looking for a skilled and compassionate cancer specialist. — Nagesh Patidar, Google review, Gota clinic listing”
★★★★★
“Dr harsh sir is a good doctor for Liver, Gastro & Cancer Surgeon in Ahmedabad thanks sir. — Milan Pareek, Google review, Gota clinic listing”
★★★★★
“We are very thankful to Dr. Harsh Shah for treating and operating on my father for gastric (stomach) cancer. From the first consultation to the surgery and follow-up, he guided us with great care and explained everything clearly. My father is doing well now, and we are extremely grateful for the treatment and support provided by Dr. Harsh Shah and his team. He is a highly experienced and compassionate doctor. We would definitely recommend Dr. Harsh Shah to anyone looking for an experienced doctor for stomach cancer treatment. Thank you, Doctor, for everything! — Moh. Ahsan, Google review, Apollo, Bhat listing”
Real Google reviews from Dr Harsh Shah’s two listings, reproduced exactly as written.
Most patients sit out of bed and take fluids on the day of surgery, eat and walk the next day, and go home within a few days after a minor or keyhole resection — later after a major resection in a cirrhotic liver. Liver blood tests and clotting are checked every day, because their trend over the first five days shows whether the remaining liver is coping.
A drain is not used routinely after an uncomplicated resection. Paracetamol is dosed carefully in cirrhosis. Fluid building up in the abdomen, confusion or drowsiness, rising jaundice, bile in a drain, fever or a racing pulse are reasons for an immediate review. A patient goes home when eating, walking, free of fever and with liver tests improving, and with a written plan for the hepatitis, alcohol or metabolic treatment that must continue.
Every HCC treatment carries risks that depend heavily on the liver around the tumour. After resection, the complication that matters most is failure of the remaining liver. The cancer also commonly returns somewhere in the liver over the years, because the whole liver remains at risk. Dr Harsh Shah gives the figures that apply to each patient’s own liver — not the most favourable ones — at the consent discussion.
After resection: bleeding needing transfusion, wound infection, clots in the leg or lung, heart or breathing problems, conversion from keyhole to open surgery, failure of the remaining liver, bile leak, collection or abscess in the abdomen, fluid in the abdomen that can persist in cirrhosis, fluid around the lung, clots in the liver’s veins, and a return to theatre. In cirrhosis, the liver can decompensate — jaundice, fluid, confusion or bleeding varices — and may not fully recover. After ablation or TACE: pain and fever, liver abscess, and worsening liver function. Medicines: side effects specific to each drug, discussed before the first dose.
After treatment, follow-up is every three months for two years — examination, AFP, liver tests and a multiphase CT or MRI — then every six months to five years, and every six months for life after that, because the cirrhotic liver can go on making new tumours. A new tumour found early may still be treatable, which is why the schedule is not optional.
At two weeks the histology is discussed and the plan for hepatitis, alcohol or fatty liver is confirmed. Antiviral adherence and viral load, alcohol support, metabolic control and endoscopy for varices continue on their own schedules. A rising AFP with a normal scan leads to a repeat scan within three months, with an MRI if the first was a CT. Transplant candidates keep their assessment current and receive bridging treatment on schedule.
The cost depends on the treatment: the extent of a resection and the length of stay, the number of ablation or TACE sessions, or the medicine chosen and how long it is given. A written estimate is given and explained before treatment.
Apollo Hospital, Bhat, works with the major insurers and cashless schemes, and the office handles pre-authorisation directly. Some cancer medicines and some transplant costs are covered differently by insurers and government schemes; this is checked before a plan is fixed, so that cost does not silently decide the treatment.
Bring: CT and MRI images on a disc or drive with reports, liver blood tests, AFP, clotting and blood counts, hepatitis B and C reports, endoscopy reports, discharge papers from any earlier treatment, a list of medicines, the insurance card and identification, and the family member who would be a possible liver donor if transplant may be discussed.
In a liver already known to be at risk, a nodule larger than one centimetre with the typical pattern on a multiphase CT or MRI is diagnosed as HCC without a biopsy. A biopsy is used when the scan is not typical, the liver is not cirrhotic, or the diagnosis is genuinely uncertain.
Because the liver left behind must be able to work. With decompensated cirrhosis, raised pressure in the liver's veins or too little remaining liver, removal could cause liver failure; ablation, TACE or transplant assessment may be safer.
Yes, for tumours within the Milan limits or brought within them by treatment. In India most transplants come from a living family donor, so referral is discussed early, at the first visit.
The response is checked after each session. If two sessions do not work, TACE is stopped, because repeating it can damage the liver and close off other treatments.
Not outside a trial. The early benefit reported for this has not held up on updated analysis, so careful scan surveillance follows resection instead.
Yes. Treating hepatitis B or C, alcohol or fatty liver continues in every patient, because it protects the liver and changes long-term outcome.
Shah’s Gastro, Cancer & Robotic Surgery Centre — Gota, Ahmedabad
Consultations, review of scans and liver tests, follow-up and surveillance after treatment.
Google: Dr Harsh Shah · 4.89 from 216 reviews
Directions to the Gota clinic · +91-63555-64601
Apollo Hospital — Bhat, Gandhinagar
Apollo Hospital International Limited, Plot No. 1 A, GIDC Bhat Industrial Estate, Bhat, Gandhinagar.
Google: Dr Harsh Shah – Robotic GI Surgeon · 4.94 from 18 reviews
Directions to Apollo, Bhat · WhatsApp +91-63555-64601
Patients come to Ahmedabad for liver cancer treatment from across Gujarat — Gandhinagar, Mehsana, Banaskantha, Nadiad, Anand, Bhavnagar, Rajkot, Jamnagar and Kutch — and from southern Rajasthan and western Madhya Pradesh.
A spot found on a liver ultrasound, or told you have liver cancer? The triple-phase CT or MRI images and report, AFP and liver blood tests, any endoscopy report and the hepatitis results can be sent ahead of the appointment, so the consultation starts with them already read; treatment is decided at the consultation, after examination. Call +91-63555-64601 · Send the reports ahead on WhatsApp
Swasth Parivar: twice a month, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
